Ciprofloxacin (hydrochloride)
(Synonyms: 盐酸环丙沙星; Bay-09867 monohydrochloride) 目录号 : GC15241
Ciprofloxacin (Bay-09867) monohydrochloride 是一种有效的、具有口服活性的拓扑异构酶 IV 抑制剂。
Cas No.:93107-08-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
Bacterial inocula are prepared by suspending colonies into Mueller-Hinton broth (CAMHB) (containing Ciprofloxacin hydrochloride) from 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) on sheep blood agar (SBA) plates that are incubated at 35°C. Suspended cultures are diluted with CAMHB to a bacterial cell density of 105 CFU/mL adjusted based on the optical density at 600 nm. To each well of the 96-well plate, 50 μL of dilutions is added for a final inoculum of ~5×104 CFU/well. Plates are incubated at 35°C. MICs are determined visually at 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) and also by absorbance at 600 nm[2]. |
|
Animal experiment: |
Female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old and 20 g (±4 g) are used in this assay. A single dose of Ciprofloxacin hydrochloride (30 mg/kg) is administered to mice (n=30) via the intraperitoneal (i.p.) route. The mice (n=3/time point/group) are culled at 1, 10, 20, or 30 min and 1, 1.5, 2, 4, 8, 12 h following Ciprofloxacin hydrochloride (Bay-09867 (hydrochloride)) administration and 1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI or CFI administration. Blood sampling points are chosen based upon the short half-life of Ciprofloxacin hydrochloride and longer half-life of CFI. Blood and lungs (whole organ) are collected post mortem for analysis. The lung doses following CFI or DRCFI administration are calculated using the concentration of Ciprofloxacin hydrochloride (Bay-09867 (hydrochloride)) in the lung samples at 1 min post-administration[3]. |
|
References: [1]. Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4. pii: S1382-6689(17)30029-7. |
|
Ciprofloxacin (hydrochloride) is a fluoroquinolone antibiotic that has antimicrobial and immunomodulatory activities [1].
Ciprofloxacin functions by inhibiting DNA gyrase and topoisomerase IV, the enzymes responsible for negative supercoiling of chromosomes and DNA strand separation, thus blocking initiation of bacterial replication. Topoisomerase IV is the primary target of ciprofloxacin in S. aureus [2].
Ciprofloxacin (hydrochloride) is a fluoroquinolone antibiotic that acts as an antimicrobial and immunomodulatory agent. In B6D2F1/J mice received radiation combined injury (CI), Ciprofloxacin significantly reduced pro-inflammatory cytokine and chemokine concentrations (IL-6 and KC), and enhanced IL-3 production. CIP also inhibited CI-induced apoptosis and autophagy in ileal villi, systemic bacterial infection, and IgA production [1]. Ciprofloxacin (hydrochloride) had been approved by FDA for management of postexposure inhalational anthrax. In animals after exposure to aerosolized B. anthracis, ciprofloxacin significantly improved survival rate. Ciprofloxacin inhibited the growth of B. anthracis with MIC90 of 0.06 μg/mL. In the USAMRIID rhesus monkey model of inhalational anthrax, the maximum concentration (Cmax) of Ciprofloxacin was 1.74 μg/mL and the minimum concentration (Cmin) was 0.17 μg/mL [3].
References:
[1]. Fukumoto R, Cary LH, Gorbunov NV, et al. Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma. PLoS One. 2013;8(3):e58389.
[2]. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92.
[3]. Meyerhoff A, Albrecht R, Meyer JM, et al. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis. 2004 Aug 1;39(3):303-8.
| Cas No. | 93107-08-5 | SDF | |
| 别名 | 盐酸环丙沙星; Bay-09867 monohydrochloride | ||
| 化学名 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, monohydrochloride | ||
| Canonical SMILES | FC1=CC2=C(C=C1N3CCNCC3)N(C4CC4)C=C(C(O)=O)C2=O.Cl | ||
| 分子式 | C17H18FN3O3 • HCl | 分子量 | 367.8 |
| 溶解度 | Water : 74 mg/mL (201.19 mM);DMSO : 7 mg/mL (19.03 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7189 mL | 13.5943 mL | 27.1887 mL |
| 5 mM | 0.5438 mL | 2.7189 mL | 5.4377 mL |
| 10 mM | 0.2719 mL | 1.3594 mL | 2.7189 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。